Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 17/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.63 |
| ▸ | HRH1 | P35367 | 5/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.63 |
| ▸ | HRH2 | P25021 | 4/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 2/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | HTR1B | P28222 | 1/20 | 0.63 |
| ▸ | HTR1E | P28566 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129893 | 1.00 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL30031624 | 0.90 | TMEM97 (0.67) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL14101174 | 0.90 | TMEM97 (0.67) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL18530311 | 0.90 | TMEM97 (0.67) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL21800358 | 0.86 | TMEM97 (0.52) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL21800344 | 0.86 | TMEM97 (0.66) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL324086 | 0.85 | TMEM97 (0.64) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1027341 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1506610 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1017246 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623369-B1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3807270-B1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-09-13 | — | — | EP | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11414435-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3807270-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| CN-112313228-A | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200317698-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| EP-3623369-A1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2020-03-18 | — | — | EP | disclosed |
| US-20150224125-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| US-9040504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014110442-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194386-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-07-10 | — | — | US | disclosed |
| EP-0775702-B1 | NOVEL QUINOLONE- OR NAPHTHYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-0882725-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6025370-A | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| US-5935952-A | ANTIBACTERIAL AGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0882725-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0775702-A1 | NOVEL QUINOLONE- OR NAPHTHYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | SSB, UACA, HLA-DRB1 | TMEM97 4357/4885SIGMAR1 4247/4885HRH1 54/4885 |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, UACA, HLA-DRB1 | TMEM97 4195/4885SIGMAR1 4238/4885HRH1 75/4885 |
| US-20200317698-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
| US-20140194386-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
| US-20150224125-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
| US-11414435-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.